PARI Respiratory Equipment’s LC Plus Reusable Nebulizer and mobile compressors were exclusively used as the aerosol delivery system to develop Sepracor’s Brovana Inhalation Solution that was approved recently by the US Food and Drug Administration for the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD). Brovana is a nebulized long-acting ß2 agonist approved as a long-term maintenance treatment for COPD and is delivered by nebulizer twice a day as prescribed by physicians.
Brovana, arformoterol tartrate, is the first long-acting bronchodilator to be developed in an inhalation solution for use with a nebulizer, which is a machine that converts liquid medication into a fine mist that is inhaled through a mouthpiece or mask, a PARI press release said. Other long-acting bronchodilators currently available in the US are formulated in dry-powder inhalers.
“PARI has a great history working with drug development companies to develop new and improved medications to enhance people’s lives. We are pleased that Sepracor’s Brovana was developed with PARI’s LC Plus and mobile nebulizers and believe that patients will appreciate the short six minute treatment times,” said Werner Gutmann, president of PARI Respiratory Equipment. “We believe the combination of Sepracor’s Brovana and PARI’s advanced aerosol delivery devices will truly better the lives of COPD sufferers.”